Published in Cancer Res on April 01, 1994
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A (2001) 3.15
Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A (1997) 2.53
Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst (1995) 1.90
Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res (1997) 1.58
Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci U S A (1996) 1.22
Prevention of hepatic tumor metastases in rats with herpes viral vaccines and gamma-interferon. J Clin Invest (1997) 1.22
Interactions between microenvironment and cancer cells in two animal models of bone metastasis. Br J Cancer (2008) 0.90
Forced expression of heat-shock protein 70 increases the secretion of Hsp70 and provides protection against tumour growth. Br J Cancer (2004) 0.86
Phase II trial of GM-CSF in advanced prostate cancer. Invest New Drugs (2001) 0.85
Neoadjuvant interleukin-12 immunogene therapy protects against cancer recurrence after liver resection in an animal model. Ann Surg (2000) 0.83
Therapy of murine mammary carcinoma metastasis with interferon gamma and MHC gene-transduced tumour cells. Br J Cancer (1996) 0.79
Development of a locally advanced orthotopic prostate tumor model in rats for assessment of combined modality therapy. Int J Oncol (2013) 0.78
Down-regulation of TGF-beta1 production restores immunogenicity in prostate cancer cells. Br J Cancer (2000) 0.77
Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development. World J Urol (2000) 0.75
The promise and reality of cancer gene therapy. Am J Hum Genet (1997) 0.75
The effectiveness of active specific immunotherapy using interferon-gamma-gene-transduced tumor cells in a murine tumor model. Surg Today (1997) 0.75
Inhibition of prostate cancer metastasis by administration of a tissue vaccine. Clin Exp Metastasis (2008) 0.75
A detailed model of reverse transcription and tests of crucial aspects. Cell (1979) 8.93
Expression of a foreign gene in myeloid and lymphoid cells derived from multipotent haematopoietic precursors. Nature (1985) 7.54
Structure of a cloned circular Moloney murine leukemia virus DNA molecule containing an inverted segment: implications for retrovirus integration. Proc Natl Acad Sci U S A (1980) 6.73
Cell-free translation of simian virus 40 early messenger RNA coding for viral T-antigen. Proc Natl Acad Sci U S A (1977) 6.57
Effect of internal viral sequences on the utility of retroviral vectors. J Virol (1987) 6.06
In vitro synthesis of a 9 kbp terminally redundant DNA carrying the infectivity of Moloney murine leukemia virus. Cell (1979) 5.78
Structure of the Abelson murine leukemia virus genome and the homologous cellular gene: studies with cloned viral DNA. Cell (1980) 5.68
Gene expression in mice after high efficiency retroviral-mediated gene transfer. Science (1985) 4.77
Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res (1997) 4.05
Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys (1998) 3.82
Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci U S A (1986) 3.68
Antibacterial nature of prostatic fluid. Nature (1968) 3.68
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res (1999) 3.58
Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell (1990) 3.36
Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med (1996) 3.01
Classification of benign diseases associated with prostatic pain: prostatitis or prostatodynia? J Urol (1978) 2.74
Genetic alterations in bladder cancer. Lancet (1993) 2.73
Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst (1995) 2.70
Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res (1999) 2.55
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol (1993) 2.42
Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med (1990) 2.41
Synthesis of a 600-nucleotide-long plus-strand DNA by virions of Moloney murine leukemia virus. Proc Natl Acad Sci U S A (1979) 2.39
Expression of genes introduced into cells by retroviral infection is more efficient than that of genes introduced into cells by DNA transfection. J Virol (1984) 2.28
Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med (2000) 2.23
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res (1993) 2.22
Role of intron-contained sequences in formation of moloney murine leukemia virus env mRNA. Mol Cell Biol (1984) 2.21
The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol (1997) 2.13
High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. Blood (1992) 2.07
Expression of the prostate-specific membrane antigen. Cancer Res (1994) 2.06
Imaging the expression of transfected genes in vivo. Cancer Res (1995) 2.05
Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections. N Engl J Med (1974) 2.05
Mechanism of RNA primer removal by the RNase H activity of avian myeloblastosis virus reverse transcriptase. J Virol (1984) 1.99
The TNM classification of prostate cancer. Prostate Suppl (1992) 1.96
Adult urological sarcoma. J Urol (1992) 1.94
Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol (1997) 1.93
Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res (1996) 1.88
Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol (1998) 1.88
Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med (1997) 1.82
Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst (1992) 1.81
Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Clin Oncol (1994) 1.78
Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector. Proc Natl Acad Sci U S A (1989) 1.78
Development and progression of clubbing and scarring in children with recurrent urinary tract infections. Radiology (1974) 1.78
Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med (1995) 1.78
Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia (1999) 1.74
Genome structure of Abelson murine leukemia virus variants: proviruses in fibroblasts and lymphoid cells. J Virol (1981) 1.73
Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res (1990) 1.73
Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol (1995) 1.71
Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res (2000) 1.68
Purification of SV-40 messenger RNA by hybridization to SV-40 DNA covalently bound to Sepharose. Biochemistry (1975) 1.66
Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol (1998) 1.64
Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J Immunol (1998) 1.62
Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol (1996) 1.60
Histopathological, cytogenetic, and molecular characterization of renal cortical tumors. Cancer Res (1991) 1.59
The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys (1991) 1.58
Clinical stage I testis cancer: long-term outcome of patients on surveillance. J Urol (1998) 1.53
Isolation of embryonal carcinoma cell lines that express integrated recombinant genes flanked by the Moloney murine leukemia virus long terminal repeat. Proc Natl Acad Sci U S A (1985) 1.51
Prostate cancer: emerging concepts. Part I. Ann Intern Med (1996) 1.51
Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. J Urol (1992) 1.50
Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis. J Clin Oncol (1996) 1.49
Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Immunol Today (1996) 1.45
Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma. Br J Urol (1996) 1.45
Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res (1995) 1.43
Effects of garlic thioallyl derivatives on growth, glutathione concentration, and polyamine formation of human prostate carcinoma cells in culture. Am J Clin Nutr (1997) 1.43
Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst (1993) 1.42
Association of the Lewis blood-group phenotype with recurrent urinary tract infections in women. N Engl J Med (1989) 1.42
Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. Urology (2001) 1.41
A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? Crit Rev Immunol (2001) 1.39
Cell-surface markers for assessing gene transfer into human hematopoietic cells. Nat Med (1996) 1.38
Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res (1991) 1.36
Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm Genome (2001) 1.36
Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol (2001) 1.36
Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to Moloney murine leukemia virus replication. Mol Cell Biol (1990) 1.34
Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. J Virol (1991) 1.34
The cell-free translation of SV40 messenger RNA. Cold Spring Harb Symp Quant Biol (1975) 1.34
Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res (1994) 1.34
Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol (2000) 1.32
Production of a discrete, infectious, double-stranded DNA by reverse transcription in virions of Moloney murine leukemia virus. Cold Spring Harb Symp Quant Biol (1979) 1.31
Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells. New Biol (1992) 1.31
Prostatic antibacterial factor. Identity and significance. Urology (1976) 1.30
Gene transfer into murine stem cells and mice using retroviral vectors. Cold Spring Harb Symp Quant Biol (1985) 1.27
Clinical and laboratory studies into the pathogenesis of malacoplakia. J Clin Pathol (1976) 1.27
Prostate-specific membrane antigen. Prostate (1997) 1.25
Uptake of radiolabeled 2'-fluoro-2'-deoxy-5-iodo-1-beta-D-arabinofuranosyluracil in cardiac cells after adenoviral transfer of the herpesvirus thymidine kinase gene: the cellular basis for cardiac gene imaging. Circulation (2000) 1.22
Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Res (1989) 1.22
Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain. J Virol (1994) 1.22
Initiation of RNA synthesis in isolated nuclei. Eur J Biochem (1977) 1.22
Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. Urology (2001) 1.22
Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol (1994) 1.21
Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers. Oncogene (2011) 1.20
An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency. Science (1991) 1.19
Urinary tract infections in children. Part I-- Young girls with non-refluxing ureters. West J Med (1974) 1.18